Tag Archives: FDA

Introduction to Functional Respiratory Imaging (FRI) for Investors and Market Analysts

For those who cannot attend our event coming Thursday at Flanders House in New York, you are welcome to register for the Webcast via following link:

https://attendee.gotowebinar.com/register/8186175617140384514

 

 

 

FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device development.

During the presentation FLUIDDA’s CEO, Dr. Jan De Backer, will present the technology and explain how it can be used to assess the potential of new respiratory drugs and devices. Some recent examples in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD) will be highlighted and an update on the regulatory status of FRI will provided.

The primary target audience for the session consists of market analysts and investors, however anyone with an interest in therapeutic development in respiratory medicine is welcome to register.

Kindly register by providing the following information, seating is limited:

Fields marked with an * are required

 

Study confirmed enhanced sensitivity of Functional Respiratory Imaging (FRI) compared to conventional lung function measures in IPF trial

” We were very impressed by the additional insights FRI brought to this clinical trial. The FRI data gave us confidence in the potential of this drug, supporting the signal observed in the lung function measurements. This type of information is very valuable when designing the next clinical trials for this compound.” Dr Piet Wigerinck, Chief… Continue Reading

FLUIDDA steps up FDA biomarker approval initiatives

In line with FDA commissioner’s, Dr Gottlieb, latest blog, FLUIDDA launched a comprehensive FDA Biomarker Approval initiative focusing on Idiopathic Pulmonary Fibrosis (#IPF), Chronic Obstructive Pulmonary Disease (#COPD), Bio-equivalence (#BE) and Lung Transplantation. As part of FDA’s critical path initiative FLUIDDA plans to submit several files demonstrating the added value of its Functional Respiratory Imaging (FRI)… Continue Reading

FLUIDDA to present and exhibit at the IPF Summit in Boston, 21-23 Aug 2017

FLUIDDA’s CEO Dr. Jan De Backer will present at IPF Summit in Boston next month. Dr De Backer will discuss how using Functional Respiratory Imaging (FRI) in clinical trials has led to valuable insights into disease progression and treatment effects. Furthermore, the use of FRI, as an FDA supported drug development tool, will be discussed.… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017